NCCN Clinical Practice Guidelines for Breast Cancer ... | 合法醫療器材資訊網
![NCCN Clinical Practice Guidelines for Breast Cancer ...](https://i.imgur.com/6y29Lx7.jpg)
AbouttheProsigna®BreastCancerPrognosticGeneSignatureAssayand...BasedonthePAM50genesignatureinitiallydiscoveredbyCharlesPerou,Ph.D....TheProsignaAssayrequiresminimalhands-ontimeandrunsonNanoString's ...
![NCCN Clinical Practice Guidelines for Breast Cancer ...](https://i.imgur.com/6y29Lx7.jpg)
SEATTLE, July 16, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for breast cancer have been updated to acknowledge that the PAM50 gene signature, commercialized as the Prosigna® Breast Cancer Prognostic Gene Signature Assay, has been clinically validated for prediction of prognosis.
"In line with our expectations, Prosigna is now recognized in the NCCN guidelines as providing clinically validated prediction of a womans risk of breast cancer recurrence," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "Discussion of Prosigna in the NCCN guidelines following our first submission is an important achievement, and we believe it establishes a solid f...
K13 | 合法醫療器材資訊網
Prosigna™ Breast Cancer Prognostic Gene Signature | 合法醫療器材資訊網
Analytical validation of the PAM50-based ... | 合法醫療器材資訊網
Development and verification of the PAM50 | 合法醫療器材資訊網
Analytical validation of the PAM50 | 合法醫療器材資訊網
RUO PAM50 CodeSet | 合法醫療器材資訊網
Analytical validation of the PAM50 | 合法醫療器材資訊網
Polaris Nanostring Prosigna Breast Cancer Gene Signature Test | 合法醫療器材資訊網
Analytical validation of the PAM50 | 合法醫療器材資訊網
NCCN Clinical Practice Guidelines for Breast Cancer ... | 合法醫療器材資訊網
![](https://i.imgur.com/6y29Lx7.jpg)
【“納斯凌”普芯娜乳癌預後基因印記檢測系統】許可證字號:衛部醫器輸字第031987號
器材品名:“納斯凌”普芯娜乳癌預後基因印記檢測系統許可證字號:衛部醫器輸字第031987號註銷狀態:註銷日期:註銷理由:有效日期:...